Mindray becomes the first Chinese company to obtain List A CE mark
CE marking, or CE mark, indicates a product's compliance with EU Directives -- among which, 98/79/EC is the directive for IVD products -- to meet specific standards of performance, quality, safety, and efficacy, which enables the commercialization of the product in the European markets.
Mindray's CE applications, including HIV and HBV (HBsAg, Anti-HBs, Anti-HBc, HBeAg, and Anti-HBe) assays, were assessed by the German Red Cross and certified by TÜV SÜD, a Germany-based global certification body for medical devices. The certification announcement, attended by TÜV SÜD representatives, President of Department of Laboratory Medicine, Chinese Society of Laboratory Medicine, professor from China's renowned tumor hospital, as well as Mindray representatives, was held during the 13th National Laboratory Medicine Conference in Hangzhou, China, on Sept. 21st.
"Infectious diseases tests are one of the most complicated and stringent CLIA assays due to complexity of samples and the existence of mutations. Over the last few years Mindray R&D team has been committed to tackling the difficulties and challenges. Now we have finally obtained CE certifications for these List A assays," Mr. Haitao Huang, Vice President of Mindray Group, said at the CE certification announcement."We have applied a number of patented technologies in the infectious disease assays to shorten the window period and reduce the endogenous interference of samples from pregnant women, the elderly, and patients with hepatic or renal diseases, etc." added Mr. Zhaoyang Li, General Manager of Mindray In-Vitro Diagnostics Business Unit.
"This is a huge achievement for a Chinese medical device company, as not all manufacturers are able to fulfill the EU requirements," President and CEO of TÜV SÜD North Asia Mr. Dirk von Wahl stated at the announcement. The CE certification not only attests to Mindray's commitment to better healthcare solutions through continued technological advancement, "(Mindray) as the first Chinese company to receive List A CE marking, it also marks China's breakthrough in the CLIA infectious diseases testing area, " commented Dr. Boshen Pan, President of Department of Laboratory Medicine, Chinese Society of Laboratory Medicine.
Behind Mindray's high quality products are its globally integrated innovation platform and world-class quality control system. Every year Mindray invests around 10% of its revenues in R&D to drive development of safe and dependable medical applications resulting in solutions that are trusted by customers worldwide and certified with international standards such as FDA and CE Marking.
Mindray has established testing laboratories covering its wide range of products to ensure they are safe, effective and reliable in all medical applications. It has China's first independently-developed Standardization Lab where the whole IVD system -- including instruments, reagents, quality controls as well as calibrators -- can be traced back to international standards to guarantee the accuracy of test results. Mindray's Reference Lab and Standardization Lab have been certified by leading testing authorities worldwide, such as ILAC-MRA/CNAS, RELA, CAP, AAB and UK NEQAS.
Open WeChat and Scan the QR code .Get the Webpage and Share on Moments.
Mindray Releases New Ceiling Supply Unit, Creating a More Optimized ICU Environment2021-03-08
Mindray Launches New BeneFusion e Series Infusion Systems, Delivering Efficiency in Every Droplet2021-02-02
Mindray Transforms Spot Check Patient Monitoring with New VS Series Vital Signs Monitors2021-01-29
Mindray in Global Actions to Combat COVID-19: Mindray at CMEF 20202020-10-20
Mindray Brings Groundbreaking New Systems to the High-End Anesthesia System Market2020-10-15